PH26680A - Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon - Google Patents
Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon Download PDFInfo
- Publication number
- PH26680A PH26680A PH39444A PH39444A PH26680A PH 26680 A PH26680 A PH 26680A PH 39444 A PH39444 A PH 39444A PH 39444 A PH39444 A PH 39444A PH 26680 A PH26680 A PH 26680A
- Authority
- PH
- Philippines
- Prior art keywords
- interferon
- treatment
- liquid nitrogen
- weeks
- week
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title claims description 62
- 229910052757 nitrogen Inorganic materials 0.000 title claims description 31
- 239000007788 liquid Substances 0.000 title claims description 29
- 238000011282 treatment Methods 0.000 title claims description 27
- 206010059313 Anogenital warts Diseases 0.000 title claims description 16
- 208000000907 Condylomata Acuminata Diseases 0.000 title claims description 11
- 108010047761 Interferon-alpha Proteins 0.000 title claims description 11
- 102000006992 Interferon-alpha Human genes 0.000 title claims description 11
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 title description 7
- 201000004201 anogenital venereal wart Diseases 0.000 title description 7
- 108020004511 Recombinant DNA Proteins 0.000 title description 6
- 108010050904 Interferons Proteins 0.000 claims description 33
- 102000014150 Interferons Human genes 0.000 claims description 33
- 230000003902 lesion Effects 0.000 claims description 33
- 229940079322 interferon Drugs 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 16
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229960003521 interferon alfa-2a Drugs 0.000 claims description 3
- 229950000038 interferon alfa Drugs 0.000 claims 1
- 210000004767 rumen Anatomy 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 25
- 238000011156 evaluation Methods 0.000 description 12
- 229960003507 interferon alfa-2b Drugs 0.000 description 7
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000002681 cryosurgery Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
- 229920006384 Airco Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000718541 Tetragastris balsamifera Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 229930185472 acuminatum Natural products 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/265,612 US4959210A (en) | 1988-11-01 | 1988-11-01 | Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26680A true PH26680A (en) | 1992-09-15 |
Family
ID=23011173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH39444A PH26680A (en) | 1988-11-01 | 1989-10-30 | Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4959210A (fr) |
| EP (2) | EP0445145A1 (fr) |
| JP (1) | JPH03503766A (fr) |
| KR (1) | KR900701309A (fr) |
| AU (1) | AU636312B2 (fr) |
| CA (1) | CA2001884A1 (fr) |
| DK (1) | DK79591A (fr) |
| IL (1) | IL92161A0 (fr) |
| MY (1) | MY106603A (fr) |
| PH (1) | PH26680A (fr) |
| WO (1) | WO1990004977A2 (fr) |
| ZA (1) | ZA898234B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
| US5165921A (en) * | 1989-01-23 | 1992-11-24 | National Geno Sciences, Inc. | Method for treating condyloma acuminatum with interferon |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| IL100415A0 (en) * | 1990-12-21 | 1992-09-06 | Schering Corp | Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases |
| US6309662B1 (en) | 1999-09-23 | 2001-10-30 | Janet Buchanan | Use of anti-inflammatory drugs for treatment of dermatological conditions |
| US7436227B2 (en) * | 2003-05-02 | 2008-10-14 | Silicon Laboratories Inc. | Dual loop architecture useful for a programmable clock source and clock multiplier applications |
| JP4889505B2 (ja) | 2004-02-02 | 2012-03-07 | アンブレツクス・インコーポレイテツド | 被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用 |
| US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
| CA3057768A1 (fr) | 2017-03-31 | 2018-10-04 | Accanis Biotech F&E Gmbh & Co Kg | Prevention et traitement de cancer de la peau non-melanome (nmsc) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| US4286690A (en) * | 1979-03-05 | 1981-09-01 | Commercial Management Corporation | Escape device |
| JPS59175416A (ja) * | 1983-03-25 | 1984-10-04 | Sunstar Inc | 皮膚および粘膜の角化異常治療用外用剤 |
| CA1321347C (fr) * | 1986-11-10 | 1993-08-17 | David C. Munch | Composition d'interferon humain leucocytaire et traitement de la peau |
-
1988
- 1988-11-01 US US07/265,612 patent/US4959210A/en not_active Expired - Fee Related
-
1989
- 1989-10-30 JP JP1511793A patent/JPH03503766A/ja active Pending
- 1989-10-30 EP EP89912698A patent/EP0445145A1/fr active Pending
- 1989-10-30 KR KR1019900701395A patent/KR900701309A/ko not_active Application Discontinuation
- 1989-10-30 IL IL92161A patent/IL92161A0/xx unknown
- 1989-10-30 ZA ZA898234A patent/ZA898234B/xx unknown
- 1989-10-30 AU AU45246/89A patent/AU636312B2/en not_active Ceased
- 1989-10-30 WO PCT/US1989/004766 patent/WO1990004977A2/fr not_active Application Discontinuation
- 1989-10-30 PH PH39444A patent/PH26680A/en unknown
- 1989-10-30 EP EP89311176A patent/EP0369632A1/fr not_active Withdrawn
- 1989-10-31 CA CA002001884A patent/CA2001884A1/fr not_active Abandoned
- 1989-10-31 MY MYPI89001527A patent/MY106603A/en unknown
-
1991
- 1991-04-30 DK DK079591A patent/DK79591A/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0369632A1 (fr) | 1990-05-23 |
| CA2001884A1 (fr) | 1990-05-01 |
| AU636312B2 (en) | 1993-04-29 |
| JPH03503766A (ja) | 1991-08-22 |
| US4959210A (en) | 1990-09-25 |
| KR900701309A (ko) | 1990-12-01 |
| MY106603A (en) | 1995-06-30 |
| DK79591D0 (da) | 1991-04-30 |
| DK79591A (da) | 1991-06-14 |
| WO1990004977A3 (fr) | 1990-06-28 |
| WO1990004977A2 (fr) | 1990-05-17 |
| ZA898234B (en) | 1990-07-25 |
| AU4524689A (en) | 1990-05-28 |
| IL92161A0 (en) | 1990-07-12 |
| EP0445145A1 (fr) | 1991-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petersen et al. | Systemic interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. | |
| RU2394589C2 (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| US6638913B1 (en) | Concentrated injection and infusion solution for intravenous administration | |
| KR101126670B1 (ko) | 약물 재구성 또는 희석을 위한 염화나트륨 용액 | |
| CA2542726A1 (fr) | Formulations pharmaceutiques, methodes et schemas posologiques pour le traitement et pour la prevention de syndromes coronaires aigus | |
| Douglas Jr et al. | A randomized trial of combination therapy with intralesional interferon α2b and podophyllin versus podophyllin alone for the therapy of anogenital warts | |
| PH26680A (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon | |
| US5028422A (en) | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon | |
| US5002764A (en) | Treatment of actinic keratoses with alpha2 interferon | |
| CA1336492C (fr) | Traitement des verrues genitales au moyen d'une combinaison de podophylline et d'interferon-alpha humain d'adn recombinant | |
| CA1295243C (fr) | Traitement des carcinomes de la cellule basale par l'administration dans la lesion d'interferon alpha humain recombinant | |
| Yao et al. | Antifungal therapy for treatment of cryptococcal meningitis | |
| Varnavides et al. | Intralesional interferon: ineffective in common viral warts | |
| KR950011889B1 (ko) | 정제된 재조합 사람 α-2 인터페론을 포함하는, 편평세포암 치료에 유용한 병소내 투여용 약제학적 조성물 | |
| Schulman et al. | Management of viral retinitis | |
| CA1295244C (fr) | Traitement des keratoses actiniques a l'aide d'interferon alpha | |
| Nelson | CHANGING TREATMENT PARADIGMS FOR HCV | |
| JPH0386835A (ja) | 劇症肝炎治療剤 | |
| Surmont et al. | Angio-Immunoblastic Lymphadenopathy | |
| BG61297B1 (bg) | метод за лечение на нuмаn рарillома virrus инфекции | |
| JP2005035913A (ja) | プラス鎖ｒｎａを遺伝情報に持つウイルスに対する治療剤 | |
| JPS62212327A (ja) | 抗菌剤 |